Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...
EF Hutton has initiated coverage on ImmunityBio Inc. (NASDAQ:IBRX), a vertically integrated biotechnology company developing ...
Parade on MSN8d
This Is One of the Most Common Signs of Bladder Cancer, According to a UrogynecologistBladder cancer makes up about 4% of cancers, most commonly affecting people 55 and older. While rates for bladder cancer are ...
Gilead, manufacturer of the TROP2-directed antibody-drug conjugate sacituzumab govitecan, made the decision to withdraw the ...
PJ DiPentino felt uneasy about his local oncologist’s plan. DiPentino’s bladder cancer had returned in a lymph node, and the ...
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...
Matthew R. Zibelman, MD, discusses differing opinions in muscle-invasive bladder cancer treatment he heard when moderating a Case-Based Roundtable event.
The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...
Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...
The study focused on urothelial carcinoma, the most common form of bladder cancer, and used advanced whole-genome sequencing ...
To mark Breast Cancer Awareness Month, we speak to inspiring Singaporeans about their journey in battling and overcoming ...
The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback